In numerous previous studies, the occurrence of the constitutively active AR-V7 splice variant lacking the C-terminal AR-LBD has been strongly linked to prostate tumor progression as well as to failures in the response to enzalutamide [15,42,47,48,49,50,51,52,53]. This evidence concerns the gene AR and prostate neoplasm.